Blocking blood vessels provides new option for large group of advanced lung cancer patients

ORLANDO, Fla. Patients with a particular type of advanced lung cancer may have a new option based on data presented here at the 2005 annual meeting of the American Society of Clinical Oncology showing that combining a drug that cuts off the cancer's blood supply with standard chemotherapy can shrink tumors and extend life.

In fact, adding the "anti-angiogenesis inhibitor" bevacizumab (Avastin) to standard chemotherapy extended median survival beyond one year for the first time among patients with advanced non-small cell, non-squamous lung cancer, reported Alan Sandler, M.D., principal investigator of the multi-center study and director of Thoracic Oncology at the Vanderbilt-Ingram Cancer Center.

As a result of the study conducted through the Eastern Cooperative Oncology Group, ECOG recommends the regimen of bevacizumab plus the chemotherapies paclitaxel and carboplatin (PCB) as the new standard treatment for patients with this stage and type of lung cancer.

"These results show, for the first time, an improvement in survival with the addition of a targeted agent to standard chemotherapy in this patient population, and first time median survival has been extended beyond one year in advanced, non-small cell lung cancer," Sandler said.

The study enrolled 878 patients with advanced, non-squamous, non-small cell lung cancer between July 2001 and April 2004. Of those, 444 were randomly assigned to receive paclitaxel and carboplatin, considered the standard therapy, and 434 were assigned to receive the chemo combination plus bevacizumab.

Median survival the point at which half the patients enrolled in the study had died was 12.5 months for patients who received bevacizumab plus chemotherapy compared to 10.2 months for patients who received standard chemotherapy alone.

"We also observed improvements in patient benefit with the bevacizumab arm, including the time between enrollment and when tumors began growing again and the proportion o

Contact: Cynthia Floyd Manley
Vanderbilt University Medical Center

Page: 1 2 3

Related biology news :

1. Blocking beta1-integrin to treat cancer
2. Blocking a premature aging syndrome with anticancer drugs
3. Blocking COX-1 slows tumor growth in mice
4. Blocking PLK-1 to beat bladder cancer
5. Blocking neurodegeneration by radiation and bone marrow transfer prevents inherited glaucoma in mice
6. Blocking cell signaling can stymie viral infections, study shows
7. Blocking cell suicide switch fails to stop prion damage in mouse brains
8. High blood pressure, low energy -- a recipe for heart failure
9. Brain blood flow gives clues to treating depression
10. Study finds gender differences in renal and other genes contributing to blood pressure
11. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause

Post Your Comments:

(Date:12/31/2019)... Kan. (PRWEB) , ... December 31, 2019 , ... ... may be an icon of its ecoregion, but researchers struggle to gather even ... find and collect. The stool can be used to identify individual animals, allowing ...
(Date:12/30/2019)... ... December 30, 2019 , ... It’s been quite a ... seen its highest sales in 2019, having hosted a multitude of team-building events and ... visited the company’s La Jolla-based venue, and the company has worked hard to accommodate ...
(Date:12/21/2019)... , ... December 20, 2019 , ... The City of ... and SAGICO was on hand to honor these heroes. Tampa welcomed these most-highly decorated ... veteran organizations and community leaders honored these distinguished service members. , The Medal of ...
Breaking Biology News(10 mins):
(Date:1/8/2020)... ... 08, 2020 , ... Anomet Products has introduced ... use in harsh environments inside or outside of the human body. , ... alloys to achieve specific properties such as corrosion-resistance, biocompatibility, or operation at temperatures ...
(Date:1/7/2020)... ... ... Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated to developing cancer metastasis ... DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, to its Board of Directors. ... Chand and Lee as new directors. They will be of great help in advancing ...
(Date:1/7/2020)... BRANFORD, Conn. (PRWEB) , ... January 06, 2020 ... ... Connecticut, today announced the second cohort of emerging biosciences ventures invited to participate ... features business education to develop fundable business plans and a professional network. All ...
(Date:12/30/2019)... ... December 30, 2019 , ... Leak ... instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries is pleased ... 11 compliant software program specific to the custom-built helium leak testing systems it ...
Breaking Biology Technology:
Cached News: